Aclaris Therapeutics (ACRS) Revenue & Revenue Breakdown
Aclaris Therapeutics Revenue Highlights
Latest Revenue (Y)
$31.25M
Latest Revenue (Q)
$2.40M
Main Segment (Y)
License and Service
Aclaris Therapeutics Revenue by Period
Aclaris Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $31.25M | 5.03% |
| 2022-12-31 | $29.75M | 340.05% |
| 2021-12-31 | $6.76M | 4.30% |
| 2020-12-31 | $6.48M | 53.35% |
| 2019-12-31 | $4.23M | -58.11% |
| 2018-12-31 | $10.09M | 499.58% |
| 2017-12-31 | $1.68M | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Aclaris Therapeutics generated $31.25M in revenue during NA 2023, up 5.03% compared to the previous quarter, and up 309.67% compared to the same period a year ago.
Aclaris Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $2.40M | -86.35% |
| 2023-12-31 | $17.57M | 89.29% |
| 2023-09-30 | $9.28M | 396.63% |
| 2023-06-30 | $1.87M | -26.07% |
| 2023-03-31 | $2.53M | -67.39% |
| 2022-12-31 | $7.75M | -59.23% |
| 2022-09-30 | $19.02M | 1144.63% |
| 2022-06-30 | $1.53M | 5.16% |
| 2022-03-31 | $1.45M | -3.20% |
| 2021-12-31 | $1.50M | -9.52% |
| 2021-09-30 | $1.66M | -9.05% |
| 2021-06-30 | $1.82M | 2.64% |
| 2021-03-31 | $1.78M | 12.47% |
| 2020-12-31 | $1.58M | 9.04% |
| 2020-09-30 | $1.45M | -29.18% |
| 2020-06-30 | $2.05M | 45.42% |
| 2020-03-31 | $1.41M | 28.49% |
| 2019-12-31 | $1.09M | 11.39% |
| 2019-09-30 | $983.00K | -83.24% |
| 2019-06-30 | $5.87M | 16.35% |
| 2019-03-31 | $5.04M | 37.39% |
| 2018-12-31 | $3.67M | 125.37% |
| 2018-09-30 | $1.63M | -55.71% |
| 2018-06-30 | $3.68M | 228.80% |
| 2018-03-31 | $1.12M | 11.91% |
| 2017-12-31 | $999.00K | 46.05% |
| 2017-09-30 | $684.00K | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | - |
Aclaris Therapeutics generated $2.40M in revenue during Q1 2024, up -86.35% compared to the previous quarter, and up 30.93% compared to the same period a year ago.
Aclaris Therapeutics Revenue Breakdown
Aclaris Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| License and Service | $28.21M | $25.10M | - | - | - |
| Contract research | $3.04M | $4.39M | $5.83M | - | - |
| Other | - | $257.00K | - | - | - |
| Other revenue | - | - | $931.00K | - | - |
| Product | - | - | - | $424.00K | - |
| Rhofade Product | - | - | - | $424.00K | - |
| Laboratory Research Revenue | - | - | - | - | $4.23M |
Aclaris Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License and Service (90.29%), and Contract research (9.71%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and Service | $1.74M | $25.58M | $994.00K | $1.64M | $6.72M | $17.90M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Contract research | $657.00K | $1.27M | $875.00K | $889.00K | $866.00K | $1.09M | $1.22M | $1.22M | $1.27M | - | - | - | - | - | - | - | - | - | - | - |
| Other | - | - | - | - | $165.00K | $30.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other revenue | - | - | - | - | - | - | $310.00K | $232.00K | $227.00K | - | - | - | - | - | - | - | - | - | - | - |
| Other Revenue | - | - | - | - | - | - | - | - | - | $244.00K | $218.00K | $242.00K | $167.00K | $118.00K | $193.00K | $218.00K | - | - | - | - |
| Laboratory Research Revenue | - | - | - | - | - | - | - | - | - | $1.42M | $1.61M | $1.53M | $1.41M | $1.33M | $1.85M | $1.19M | $1.09M | $983.00K | - | - |
| Eskata Product | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $272.00K | $72.00K |
| Product | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.98M | $3.78M |
| Rhofade Product | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.71M | $3.71M |
Aclaris Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: License and Service (72.60%), and Contract research (27.40%).
Aclaris Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IQV | IQVIA | $14.98B | $3.81B |
| ICLR | ICON Public Limited Company | $8.12B | $2.09B |
| QGEN | Qiagen | $1.97B | $458.80M |
| MEDP | Medpace | $1.89B | $528.10M |
| RDNT | RadNet | $1.62B | $459.71M |
| SHC | Sotera Health Company | $1.05B | $276.59M |
| NEOG | Neogen | $924.22M | $216.96M |
| MYGN | Myriad Genetics | $678.40M | $191.90M |
| GTH | Genetron | $650.71M | $201.32M |
| CSTL | Castle Biosciences | $219.79M | $87.00M |
| OLK | Olink AB (publ) | $169.91M | $28.59M |
| BDSX | Biodesix | $49.09M | $14.82M |
| ACRS | Aclaris Therapeutics | $31.25M | $2.40M |
| PRE | Prenetics Global | $21.74M | $6.41M |
ACRS Revenue FAQ
What is Aclaris Therapeutics’s yearly revenue?
Aclaris Therapeutics's yearly revenue for 2023 was $31.25M, representing an increase of 5.03% compared to 2022. The company's yearly revenue for 2022 was $29.75M, representing an increase of 340.05% compared to 2021. ACRS's yearly revenue for 2021 was $6.76M, representing an increase of 4.30% compared to 2020.
What is Aclaris Therapeutics’s quarterly revenue?
Aclaris Therapeutics's quarterly revenue for Q1 2024 was $2.4M, a -86.35% decrease from the previous quarter (Q4 2023), and a -5.14% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $17.57M, a 89.29% increase from the previous quarter (Q3 2023), and a 126.62% increase year-over-year (Q4 2022). ACRS's quarterly revenue for Q3 2023 was $9.28M, a 396.63% increase from the previous quarter (Q2 2023), and a -51.19% decrease year-over-year (Q3 2022).
What is Aclaris Therapeutics’s revenue growth rate?
Aclaris Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 362.19%, and for the last 5 years (2019-2023) was 639.27%.
What are Aclaris Therapeutics’s revenue streams?
Aclaris Therapeutics's revenue streams in c 23 are License and Service, and Contract research. License and Service generated $28.21M in revenue, accounting 90.29% of the company's total revenue, up 12.41% year-over-year. Contract research generated $3.04M in revenue, accounting 9.71% of the company's total revenue, down -30.94% year-over-year.
What is Aclaris Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Aclaris Therapeutics was License and Service. This segment made a revenue of $28.21M, representing 90.29% of the company's total revenue.